Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9299.121 | 1.0463 | 1.2318 | 0.4126 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9299.121 | 1.0869 | 1.4476 | 0.4126 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9299.121 | 0.9859 | 0.9323 | 0.4126 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9299.121 | 0.1500 | -0.9799 | 0.4126 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 18.4 | uM | 9299.121 | 0.1040 | -0.9917 | 0.4126 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 92 | uM | 9299.121 | 0.0217 | -0.9998 | 0.4126 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 10031.034 | 1.0863 | 1.2162 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 10031.034 | 0.9988 | 0.9970 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 10031.034 | 1.0525 | 1.1311 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 10031.034 | 1.0031 | 1.0077 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.138 | uM | 10031.034 | 1.0775 | 1.1939 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.69 | uM | 10031.034 | 0.9435 | 0.8607 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.45 | uM | 10031.034 | 0.1286 | -0.8428 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 17.2 | uM | 10031.034 | 0.1157 | -0.8621 | 0.8064 | |
| HCC1428 | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10031.034 | 0.0174 | -0.9868 | 0.8064 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7825.007 | 1.1008 | 1.1304 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7825.007 | 1.0393 | 1.0514 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7825.007 | 1.0461 | 1.0602 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7825.007 | 1.1448 | 1.1861 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7825.007 | 1.0529 | 1.0690 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7825.007 | 0.8837 | 0.8438 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7825.007 | 0.8154 | 0.7487 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7825.007 | 0.5662 | 0.3756 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7825.007 | 0.3419 | -0.0130 | 1.5199 | |
| HCC1569 | HER2amp | Basal A | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9347.121 | 1.1099 | 1.1489 | 1.4523 |